Literature DB >> 9736565

Efficacy of nikkomycin Z in the treatment of murine histoplasmosis.

J R Graybill1, L K Najvar, R Bocanegra, R F Hector, M F Luther.   

Abstract

Immune-competent ICR and BALB/c athymic (nude) mice were infected intravenously with Histoplasma capsulatum and treated with either fluconazole or nikkomycin Z or 5% dextrose (controls). In immune-competent ICR mice, fluconazole and nikkomycin Z both prolonged survival when given at 5 mg/kg of body weight twice daily. When administered in doses as low as 2.5 mg/kg twice daily, nikkomycin Z reduced fungal counts in both the spleen and liver. When both drugs were combined, there was no antagonism, and in combined therapy spleen and liver counts were reduced more than for either drug alone. However, nikkomycin Z had no effect on brain fungal burden. In nude mice fluconazole and nikkomycin Z had an additive effect in prolongation of survival and reduction of liver and spleen burden. Nikkomycin Z is well tolerated, is at least as effective as fluconazole, and may interact beneficially with fluconazole for treatment of murine histoplasmosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736565      PMCID: PMC105835     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.

Authors:  L J Wheat; P A Connolly-Stringfield; R L Baker; M F Curfman; M E Eads; K S Israel; S A Norris; D H Webb; M L Zeckel
Journal:  Medicine (Baltimore)       Date:  1990-11       Impact factor: 1.889

2.  Role of three chitin synthase genes in the growth of Candida albicans.

Authors:  T Mio; T Yabe; M Sudoh; Y Satoh; T Nakajima; M Arisawa; H Yamada-Okabe
Journal:  J Bacteriol       Date:  1996-04       Impact factor: 3.490

3.  Role of L3T4+ T cells in host defense against Histoplasma capsulatum.

Authors:  A M Gomez; W E Bullock; C L Taylor; G S Deepe
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

Review 4.  Compounds active against cell walls of medically important fungi.

Authors:  R F Hector
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

5.  Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis.

Authors:  R F Hector; B L Zimmer; D Pappagianis
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

6.  Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo.

Authors:  J P Gaughran; M H Lai; D R Kirsch; S J Silverman
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

7.  Histoplasmosis in the acquired immune deficiency syndrome.

Authors:  L J Wheat; T G Slama; M L Zeckel
Journal:  Am J Med       Date:  1985-02       Impact factor: 4.965

Review 8.  Antibiotics that inhibit fungal cell wall development.

Authors:  M Debono; R S Gordee
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

9.  Experimental chemotherapy of histoplasmosis in nude mice.

Authors:  D M Williams; J R Graybill; D J Drutz
Journal:  Am Rev Respir Dis       Date:  1979-10

10.  Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.

Authors:  R F Hector; K Schaller
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

View more
  10 in total

1.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

Review 2.  Drugs in Clinical Development for Fungal Infections.

Authors:  Maria F Gonzalez-Lara; Jose Sifuentes-Osornio; Luis Ostrosky-Zeichner
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

3.  Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model.

Authors:  J Goldberg; P Connolly; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; E Brizendine; R Hector; J Wheat
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

4.  Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

Authors:  K V Clemons; M Martinez; L Calderon; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  In vitro efficacy of nikkomycin Z against the human isolate of the microsporidian species Encephalitozoon hellem.

Authors:  E Bigliardi; A M Bernuzzi; S Corona; S Gatti; M Scaglia; L Sacchi
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 6.  Regulation of expression, activity and localization of fungal chitin synthases.

Authors:  Luise E Rogg; Jarrod R Fortwendel; Praveen R Juvvadi; William J Steinbach
Journal:  Med Mycol       Date:  2011-04-28       Impact factor: 4.076

7.  Pharmacokinetics of nikkomycin Z after single rising oral doses.

Authors:  David E Nix; Robert R Swezey; Richard Hector; John N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

Review 8.  Emergomycosis, an Emerging Systemic Mycosis in Immunocompromised Patients: Current Trends and Future Prospects.

Authors:  Arghadip Samaddar; Anuradha Sharma
Journal:  Front Med (Lausanne)       Date:  2021-04-23

Review 9.  Hope on the Horizon: Novel Fungal Treatments in Development.

Authors:  Adriana M Rauseo; Ariella Coler-Reilly; Lindsey Larson; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

Review 10.  Nikkomycin Z-Ready to Meet the Promise?

Authors:  David J Larwood
Journal:  J Fungi (Basel)       Date:  2020-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.